Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988;35(4):419-21.
doi: 10.1007/BF00561375.

Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon

B Marasini  1 , M L Biondi, E Bianchi, P Dell'Orto, A Agostoni
Affiliations
Clinical Trial

Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon

B Marasini et al. Eur J Clin Pharmacol. 1988.

Abstract

In a double-blind, placebo cross-over study in 14 patients with Raynaud's disease, oral ketanserin 40 mg b.d. for two months reduced the number of digital ischaemic attacks in 36% of the patients, with no difference between primary or secondary cases. Intraplatelet and circulating serotonin concentrations were significantly higher in patients than in controls. During treatment there was a significant decrease in intraplatelet serotonin, but no change in circulating serotonin or in the amount of serotonin released by platelets in vitro. The results suggest that oral ketanserin is of minor help in Raynaud's phenomenon and they support a role for serotonin in the disorder.

PubMed Disclaimer

References

    1. Int J Cardiol. 1988 Jun;19(3):335-9 - PubMed
    1. J Rheumatol. 1986 Apr;13(2):337-40 - PubMed
    1. Arch Dermatol Res. 1986;279(1):3-7 - PubMed
    1. Angiology. 1960 Jun;11:151-67 - PubMed
    1. Microcirc Endothelium Lymphatics. 1985;2(6):657-85 - PubMed

Publication types

LinkOut - more resources